Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;8(12):978-986.
doi: 10.1016/S2213-8587(20)30342-9. Epub 2020 Oct 28.

Catecholamine physiology and its implications in patients with COVID-19

Sriram Gubbi  1 , Matthew A Nazari  2 , David Taieb  3 , Joanna Klubo-Gwiezdzinska  1 , Karel Pacak  4
Affiliations
Review

Catecholamine physiology and its implications in patients with COVID-19

Sriram Gubbi et al. Lancet Diabetes Endocrinol. 2020 Dec.

Abstract

The risk factors for severe COVID-19 are diverse, yet closely resemble the clinical manifestations of catecholamine excess states (eg, hypertension, cardiovascular disease, immune dysregulation, and hyperglycaemia), suggesting a potentially common basis for disease. Unfortunately, severe illness (eg, respiratory failure, compromised cardiac function, and shock) incurred by COVID-19 hinders the direct study of catecholamines in these patients, especially among those on multiple medications or those on adrenaline or noradrenaline infusions, or both. Phaeochromocytoma and paraganglioma (PPGL) are tumours that secrete catecholamines, namely adrenaline and noradrenaline, often in excess. PPGL are well studied disease processes in which the effects of catecholamines are easily discernible and therefore their potential biochemical and physiological influences in patients with COVID-19 can be explored. Because catecholamines are expected to have a role in patients with critical illness, patients on vasopressor infusions, and patients who sustain some acute and chronic physical stresses, the challenges involved in the management of catecholamine excess states are directly relevant to the treatment of patients with COVID-19. In this Personal View, we discuss the complex interplay between catecholamines and COVID-19, and the management of catecholamine excess states, while referencing relevant insights derived from the study of PPGL.

PubMed Disclaimer

Figures

Figure
Figure
The various potential interactions between COVID-19 and PPGL The figure was designed by Alan Hoofring from the Medical Arts Design Section of the US National Institute of Health. AR=adrenoceptor. IL=interleukin. PPGL=phaeochromocytoma and paraganglioma. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. TNF=tumour necrosis factor.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. - PMC - PubMed
    1. Williamson EJ, Walker AJ, Bhaskaran K. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature. 2020;584:430–436. - PMC - PubMed
    1. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open. 2020;3 - PMC - PubMed
    1. Garcia LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11 - PMC - PubMed
    1. Gattinoni L, Chiumello D, Caironi P. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46:1099–1102. - PMC - PubMed

Publication types